Compositions and methods for treating polycystic ovary syndrome
BUDC, either alone or combined with UDCA, provides a therapeutic approach to address PCOS symptoms by improving insulin resistance and hormonal balance, offering a potential cure beyond symptom management.
Patent Information
- Application Number
- PCT/CN2026/094758
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-06
- Filing Date
- 2026-05-06
- Publication Date
- 2026-11-12
AI Technical Summary
Current treatments for polycystic ovary syndrome (PCOS) focus on symptom management rather than cure, and there is an urgent need for novel therapeutics that can safely and effectively treat or manage the condition.
The use of berberine ursodeoxycholate (BUDC) as a pharmaceutical composition, either alone or in combination with ursodeoxycholic acid (UDCA), for treating PCOS, either as monotherapy or as an adjuvant, administered in various forms and dosages to address symptoms such as polycystic ovaries, infertility, and irregular menstrual cycles.
BUDC effectively reduces symptoms of PCOS, including polycystic ovaries, infertility, and irregular menstrual cycles, by improving insulin resistance and hormonal balance, as demonstrated in animal models.
Smart Images

Figure CN2026094758_12112026_PF_FP_ABST
Abstract
Description
COMPOSITIONS AND METHODS FOR TREATING POLYCYSTIC OVARY SYNDROMETechnical Field of the Invention
[0001] The invention generally relates to pharmaceutical compositions and methods for therapeutic use thereof. In particular, the invention relates to pharmaceutical compositions and methods of using berberine ursodeoxycholate (BUDC) for treating and / or preventing polycystic ovary syndrome, or a related disease or condition, as monotherapy, in a combination therapy with other agents, or as an adjuvant.Background of the Invention
[0002] Polycystic ovary syndrome (a. k. a., polycystic ovarian syndrome, PCOS) is a heterogeneous disorder with an unknown etiology. It is generally understood to be caused by a combination of genetic and environmental factors. Women with PCOS experience difficulties getting pregnant, and are prone to miscarriage, gestational diabetes, pregnancy-induced hypertension and preeclampsia, high fetal morbidity, and perinatal mortality. The primary characteristics ofPCOS include hyperandrogenism, anovulation, insulin resistance, and neuroendocrine disruption. PCOS not only affects women of reproductive age (with a prevalence of 9%to 18%depending on the diagnostic criteria) , but also affects adolescents and postmenopausal women. Risk factors include obesity, a lack of physical exercise, and a family history of someone with the condition. Diagnosis is based on two of the following three findings: anovulation, high androgen levels, and ovarian cysts. Cysts may be detectable by ultrasound. PCOS is increasingly recognized as a multifactorial metabolic condition with significant long-term health consequences, including an elevated risk of cardiovascular disease and type 2 diabetes. (Ionescu, et al. 2023 Life 13, 125; De Leo, et al. 2016 Reproductive Biology and Endocrinology 14 (1) : 38; Dumesic, et al. 2015 Endocrine Reviews 36 (5) : 487-525; Crespo, et al. 2018 Archives of Endocrinology and Metabolism 62 (3) : 352-361; Crespo, et al. 2018 Archives of Endocrinology and Metabolism 62 (3) : 352-361; Polycystic Ovary Syndrome: Condition Information" National Institute of Child Health and Human Development; Teede, et al. 2021 The Journal of Clinical Endocrinology&Metabolism 107 (3) : e1321-e1322. )
[0003] Currently, there are no cures for PCOS. Treatment focuses on managing symptoms and often involves lifestyle changes such as weight loss, healthy eating and exercise to reduce the risk of long-term health problems. Medications may be taken to help regulate periods and manage hormone levels. Treatments for improving fertility include weight loss, metformin, and ovulation induction using clomiphene or letrozole. In vitro fertilization may be considered by patients when other measures are ineffective. (Mortada, et al. 2015 FP Essentials 435: 30–42; Giallauria, et al. 2009 Seminars in Reproductive Medicine 27 (4) : 306–315; Morrow-Baez K 2018 Thriving with PCOS: Lifestyle Strategies to Successfully Manage Polycystic Ovary Syndrome Rowman&Littlefield Publishers. )
[0004] Thus, novel therapeutics and methods that can safely and effectively treat or manage PCOS are urgently needed.Summary of the Invention
[0005] The invention is based in part on the unexcepted discovery that BUDC is useful for the safe and effective treatment of PCOS.
[0006] In one aspect, the invention generally relates to a method for treating PCOS, or a related disease or condition, comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising BUDC.
[0007] In another aspect, the invention generally relates to a unit dosage form of BUDC comprising BUDC a pharmaceutically acceptable excipient, carrier, or diluent, for treating PCOS, or a related disease or condition.
[0008] In yet another aspect, the invention generally relates to a method for treating PCOS, or a related disease or condition, comprising administering to a subject in need thereof (i) a therapeutically effective amount of BBR, or a pharmaceutically acceptable form thereof, and (ii) a therapeutically effective amount of UDCA, or a pharmaceutically acceptable form thereof.
[0009] In yet another aspect, the invention generally relates to a kit that comprises (i) a unit dosage form of BBR, (ii) a unit dosage form of UDCA, and (iii) instructions for administration thereof for treating PCOS or a related disease or condition.
[0010] In yet another aspect, the invention generally relates to use of (a) a therapeutically effective amount of BUDC, or a pharmaceutically acceptable form thereof, for treating PCOS, or a related disease or condition.
[0011] In yet another aspect, the invention generally relates to use of (i) a therapeutically effective amount of BBR, or a pharmaceutically acceptable form thereof, and (ii) a therapeutically effective amount of UDCA, or a pharmaceutically acceptable form thereof, for treating PCOS, or a related disease or condition.Brief Description of the Drawings
[0012] FIG. 1 shows exemplary data on body weight of rats in each group during treatment.
[0013] FIG. 2 shows exemplary data on the percentage of diestrus days in each group.
[0014] FIG. 3 shows exemplary data on the levels of fasting glucose, fasting insulin and HOMA-IR in each group.
[0015] FIG. 4 shows exemplary data on the levels of cholesterol, triglycerides and LDL-c in each group at the end of the study.
[0016] FIG. 5 shows exemplary data on the weight of ovarian and uterine in each group at the end of the study.
[0017] FIG. 6 shows exemplary data on the follicular cyst count and corpus luteum count from H&E staining of ovaries in each group.Definitions
[0018] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. General principles of organic chemistry, as well as specific functional moieties and reactivity, are described in “Organic Chemistry” , Thomas Sorrell, University Science Books, Sausalito: 2006.
[0019] As used in the present disclosure, the following words and phrases are generally intended to have the meanings as set forth below unless expressly indicated otherwise or the context in which they are used indicates otherwise.
[0020] In this specification and the appended claims, the singular forms "a, " "an, " and "the" include plural reference, unless the context clearly dictates otherwise.
[0021] The term “and / or” is used in this disclosure to mean either “and” or “or” unless the context clearly dictates otherwise.
[0022] As used herein, “at least” a specific value is understood to be that value and all values greater than that value.
[0023] Applicant’s disclosure is described herein in preferred embodiments with reference to the Figures, in which like numbers represent the same or similar elements. Reference throughout this specification to “one embodiment, ” “an embodiment, ” or similar language means that a particular feature, structure, or characteristic described in connection with the embodiment is included in at least one embodiment of the present invention. Thus, appearances of the phrases “in one embodiment, ” “in an embodiment, ” and similar language throughout this specification may, but do not necessarily, all refer to the same embodiment.
[0024] The term “comprising” , when used to define compositions and methods, is intended to mean that the compositions and methods include the recited elements, but do not exclude other elements. The term “consisting essentially of” , when used to define compositions and methods, shall mean that the compositions and methods include the recited elements and exclude other elements of any essential significance to the compositions and methods. For example, “consisting essentially of” refers to administration of the pharmacologically active agents expressly recited and excludes pharmacologically active agents not expressly recited. The term consisting essentially of does not exclude pharmacologically inactive or inert agents, e.g., pharmaceutically acceptable excipients, carriers or diluents. The term “consisting of” , when used to define compositions and methods, shall mean excluding trace elements of other ingredients and substantial method steps. Embodiments defined by each of these transition terms are within the scope of this invention.
[0025] In the application, where an element or component is said to be included in and / or selected from a list of recited elements or components, it should be understood that the element or component can be any one of the recited elements or components, or the element or component can be selected from a group consisting of two or more of the recited elements or components.
[0026] Where compositions and kits are described as having, including, or comprising specific components, or where processes and methods are described as having, including, or comprising specific steps, it is contemplated that, additionally, there are compositions and kits of the present invention that consist essentially of, or consist of, the recited components, and that there are processes and methods according to the present invention that consist essentially of, or consist of, the recited processing steps.
[0027] Unless specifically stated or obvious from context, as used herein, the term “about” is understood as within a range of normal tolerance in the art, for example within 2 standard deviations of the mean. About can be understood as within 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.1%, 0.05%, or 0.01%of the stated value. Unless otherwise clear from context, all numerical values provided herein can be modified by the term about.
[0028] At various places in the present specification, variables or parameters are disclosed in groups or in ranges. It is specifically intended that the description include each and every individual subcombination of the members of such groups and ranges. For example, a range of 1 to 16 is understood to include any number, combination of numbers, or sub-range from the group consisting 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 16.
[0029] As used herein, the term “effective amount” of an active agent refers to an amount sufficient to elicit the desired biological response. As will be appreciated by those of ordinary skill in this art, the effective amount of a compound of the invention may vary depending on such factors as the desired biological endpoint, the pharmacokinetics of the compound, the disease being treated, the mode of administration, and the patient.
[0030] As used herein, “pharmaceutical composition” refers to the combination of a therapeutically active agent with one or more pharmaceutically acceptable excipients, carriers, or diluents, making the composition especially suitable for diagnostic or therapeutic use in vivo or ex vivo.
[0031] As used herein, the term “pharmaceutically acceptable excipient, carrier, or diluent” refers to a pharmaceutically acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying or transporting the subject pharmaceutical agent from one organ, or portion of the body, to another organ, or portion of the body. Each carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient. Some examples of materials which can serve as pharmaceutically-acceptable carriers include: sugars, such as lactose, glucose and sucrose; starches, such as corn starch and potato starch; cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients, such as cocoa butter and suppository waxes; oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols, such as propylene glycol; polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; esters, such as ethyl oleate and ethyl laurate; agar; buffering agents, such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethyl alcohol; phosphate buffer solutions; and other non-toxic compatible substances employed in pharmaceutical formulations. Wetting agents, emulsifiers and lubricants, such as sodium lauryl sulfate, magnesium stearate, and polyethylene oxide-polypropylene oxide copolymer as well as coloring agents, release agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the compositions.
[0032] As used herein, the term “subject” refers to any animal (e.g., a mammal) , including, but not limited to humans, non-human primates, rodents, and the like, which is to be the recipient of a particular treatment. Typically, the terms “subject” and “patient” are used interchangeably herein in reference to a human subject. A “subject” to which administration is contemplated includes, but is not limited to, humans (i.e., a male or female of any age group, e.g., a pediatric subject (e.g., infant, child, adolescent) or adult subject (e.g., young adult, middle–aged adult or senior adult) ) and / or a non-human animal, e.g., a mammal such as primates (e.g., cynomolgus monkeys, rhesus monkeys) , cattle, pigs, horses, sheep, goats, rodents, cats, and / or dogs. In certain embodiments, the subject is a human. In certain embodiments, the subject is a non-human animal.
[0033] As used herein, “administering” means oral administration, administration as a pulmonary, suppository, intramuscular administration, intrathecal administration, intranasal administration or subcutaneous administration, or the implantation of a slow-release device, e.g., a mini-osmotic pump, to a subject. Administration is by any route, including transmucosal (e.g., buccal, sublingual, palatal, gingival, nasal, vaginal, rectal, or) . Parenteral administration includes, e.g., intramuscular and subcutaneous. Other modes of delivery include, but are not limited to, the use of liposomal formulations, etc. By “co-administer” it is meant that a composition described herein is administered at the same time, just prior to, or just after the administration of one or more additional therapies (e.g., therapeutic agent, chemotherapeutic, or treatment for a neurodegenerative disease) . The compound of formula (I) can be administered alone or can be co-administered to the patient. Co-administration is meant to include simultaneous or sequential administration of the compound individually or in combination (more than one compound or agent) . Thus, the preparations can also be combined, when desired, with other active substances (e.g., to reduce metabolic degradation) .
[0034] The terms “disease, ” “disorder, ” and “condition” are used interchangeably herein.
[0035] As used herein, the term “treating” , “reducing” , or “preventing” a disease or disorder refers to ameliorating such a condition before or after it has occurred. As compared with an equivalent untreated control, such reduction or degree of prevention is at least 5%, 10%, 20%, 40%, 50%, 60%, 80%, 90%, 95%, or 100%as measured by any standard technique. The terms “treat, ” “treating” and “treatment” contemplate an action that occurs while a subject is suffering from the specified disease, disorder or condition, which reduces the severity of the disease, disorder or condition, or retards or slows the progression of the disease, disorder or condition ( “therapeutic treatment” ) , and also contemplates an action that occurs before a subject begins to suffer from the specified disease, disorder or condition ( “prophylactic treatment” ) . In one embodiment, the compounds provided herein are contemplated to be used in methods of therapeutic treatment wherein the action occurs while a subject is suffering from the specified disease, disorder or condition and results in a reduction in the severity of the disease, disorder or condition, or retardation or slowing of the progression of the disease, disorder or condition. In an alternate embodiment, the compounds provided herein are contemplated to be used in methods of prophylactic treatment wherein the action occurs before a subject begins to suffer from the specified disease, disorder or condition and results in preventing a disease, disorder or condition, or one or more symptoms associated with the disease, disorder or condition, or preventing the recurrence of the disease, disorder or condition.
[0036] The described features, structures, or characteristics of Applicant’s disclosure may be combined in any suitable manner in one or more embodiments. In the description, herein, numerous specific details are recited to provide a thorough understanding of embodiments of the invention. One skilled in the relevant art will recognize, however, that Applicant’s composition and / or method may be practiced without one or more of the specific details, or with other methods, components, materials, and so forth. In other instances, well-known structures, materials, or operations are not shown or described in detail to avoid obscuring aspects of the disclosure.
[0037] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. Although any methods and materials similar or equivalent to those described herein can also be used in the practice or testing of the present disclosure, the preferred methods and materials are now described. Methods recited herein may be carried out in any order that is logically possible, in addition to a particular order disclosed.Detailed Description of the Invention
[0038] The invention provides methods and compositions of BUDC for the treatment and / or prevention of PCOS, or a related disease or condition.
[0039] BUDC (also referred to as BUDCA or HTD1801) is an ionic salt of berberine (BBR) and ursodeoxycholic acid (UDCA) , represented by The compound was disclosed in WO 2016 / 015634 A1 (PCT / CN2015 / 085350) and WO 2018 / 205987 A1 (PCT / CN2018 / 086461) , the content of each of which is incorporated herein by reference in its entirety.
[0040] BUDC is under investigation for the treatment of type 2 diabetes (T2DM) , primary sclerosing cholangitis (PSC) , primary biliary cirrhosis (PBC) , non-alcoholic steatohepatitis (NASH) or metabolic dysfunction-associated steatohepatitis (MASH) among others. BUDC is an ionic salt formed with 1: 1 stoichiometry between BBR and UDCA and offers unique physico-chemical properties including enhanced bioavailability of BBR within the gut.
[0041] In one aspect, the invention generally relates to a method for treating PCOS, or a related disease or condition, comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising BUDC.
[0042] In certain embodiments, the subject under treatment suffers from one or more symptoms associated with PCOS selected from polycystic ovaries, infertility, hyperandrogenism and irregular menstrual cycles.
[0043] In certain embodiments, the method is for treating polycystic ovaries.
[0044] In certain embodiments, the method is for treating infertility associated with PCOS.
[0045] In certain embodiments, the method is treating hyperandrogenism associated with PCOS.
[0046] In certain embodiments, the method is for treating irregular menstrual cycles associated with PCOS.
[0047] In certain embodiments of the methods disclosed herein, BUDC is administered at a daily dosage in the range of about 50 mg to about 5,000 mg (e.g., about 100 mg to about 5,000 mg, about 250 mg to about 5,000, about 500 mg to about 3,000 mg, about 750 mg to about 3,000 mg, about 500 mg to about 2,500 mg, about 1,000 mg to about 3,000 mg, about 1,500 mg to about 3,000 mg, about 250 mg to about 2,000 mg, about 250 mg to about 1,500 mg, about 250 mg to about 1,000 mg, about 500 mg to about 1,500 mg, about 750 mg to about 1,250 mg) for a time period of about 1 day to about 24 weeks (e.g., about 1 day to about 12 weeks, about 1 day to about 6 weeks, about 1 day to about 4 weeks, about 1 day to about 2 weeks, about 1 week to about 24 weeks, about 4 weeks to 24 weeks, about 6 weeks to 24 weeks) or longer.
[0048] In certain embodiments of the methods herein, the subject is administered from about 500 mg / day to about 2,500 mg / day of BUDC.
[0049] In certain embodiments of the methods herein, the subject is treated for a period of about 2 weeks to about 12 months (e.g., about 2 weeks to about 4 weeks, about 1 month to about 2 months, about 2 months to about 6 months, about 6 months to about 12 months) . In certain embodiments, the subject is treated for a period of about 1 month to about 6 months.
[0050] In certain embodiments of the methods herein, BUDC is in the form ofForm A.
[0051] In certain embodiments of the methods herein, BUDC is a hydrate (e.g., a hemi-nonahydrate) .
[0052] In certain embodiments, BUDC is administered as a monotherapy.
[0053] In certain embodiments, BUDC is administered as an adjuvant in treatment of herein discussed diseases or conditions.
[0054] In another aspect, the invention generally relates to a unit dosage form of BUDC, e.g., comprising from about 500 mg to about 2,500 mg of BUDC, and a pharmaceutically acceptable excipient, carrier, or diluent, for treating PCOS, or a related disease or condition. In certain embodiments, the unit dosage form comprises from about 750 mg to about 1,250 mg of BUDC and a pharmaceutically acceptable excipient, carrier, or diluent.
[0055] In certain embodiments, the unit dosage form is for treating one or more symptoms associated with PCOS selected from polycystic ovaries, infertility, hyperandrogenism and irregular menstrual cycles.
[0056] In certain embodiments of the unit dosage form, BUDC is in the form of Form A.
[0057] In certain embodiments of the unit dosage form, BUDC is a hydrate (e.g., a hemi-nonahydrate) .
[0058] In certain embodiments, the unit dosage form is capsule.
[0059] In certain embodiments, the unit dosage form is tablet.
[0060] In yet another aspect, the invention generally relates to a method for treating PCOS, or a related disease or condition, comprising administering to a subject in need thereof (i) a therapeutically effective amount of BBR, or a pharmaceutically acceptable form thereof, and (ii) a therapeutically effective amount of UDCA, or a pharmaceutically acceptable form thereof.
[0061] In certain embodiments, the subject under treatment suffers from one or more symptoms associated with PCOS selected from polycystic ovaries, infertility, hyperandrogenism and irregular menstrual cycles.
[0062] In certain embodiments, the method is for treating polycystic ovaries.
[0063] In certain embodiments, the method is for treating infertility associated with PCOS.
[0064] In certain embodiments, the method is treating hyperandrogenism associated with PCOS.
[0065] In certain embodiments, the method is for treating irregular menstrual cycles associated with PCOS.
[0066] In yet another aspect, the invention generally relates to a kit that comprises (i) a unit dosage form of BBR, (ii) a unit dosage form of UDCA, and (iii) instructions for administration thereof for treating PCOS or a related disease or condition.
[0067] In certain embodiments, the kit is for treating one or more symptoms associated with PCOS selected from polycystic ovaries, infertility, hyperandrogenism and irregular menstrual cycles.
[0068] In yet another aspect, the invention generally relates to use of (a) a therapeutically effective amount of BUDC, or a pharmaceutically acceptable form thereof, for treating PCOS, or a related disease or condition.
[0069] In certain embodiments, the use of BUDC is for treating one or more symptoms associated with PCOS selected from polycystic ovaries, infertility, hyperandrogenism and irregular menstrual cycles.
[0070] In yet another aspect, the invention generally relates to use of (i) a therapeutically effective amount of BBR, or a pharmaceutically acceptable form thereof, and (ii) a therapeutically effective amount of UDCA, or a pharmaceutically acceptable form thereof, for treating PCOS, or a related disease or condition.
[0071] In certain embodiments, the use of BBR and UDCA is for treating one or more symptoms associated with PCOS selected from polycystic ovaries, infertility, hyperandrogenism and irregular menstrual cycles.
[0072] Various solid and crystalline forms of BUDC may be employed in the invention disclosed herein.
[0073] In certain embodiments, Form A of BUDC, having an X-ray powder diffraction (XRPD) pattern comprising one or more peaks at 2θvalues selected from the group consisting of: 3.98, 7.06, 7.34, 7.93, 8.79, 9.47, 11.70, 11.94, 12.34, 12.55, 13.90, 14.17, 15.14, 15.50, 16.16, 16.54, 16.78, 17.53, 17.67, 18.23, 19.03, 19.98, 20.87, 21.13, 21.96, 23.49, 24.24, 24.97, 25.50, 26.63, 27.60, 28.06, 28.63, 29.40 and 30.49° (±0.2°) obtained using Cu Kαradiation ( intensity ratioλ2 / λ1=0.50) , is employed.
[0074] In certain embodiments, Form B of BUDC, having an X-ray powder diffraction (XRPD) pattern comprising one or more peaks at 2θvalues selected from the group consisting of: 7.39, 9.31, 12.41, 13.14, 14.37, 14.76, 15.53, 18.65, 21.79, 22.87, 25.27, 25.53 and 28.12° (±0.2°) obtained using Cu Kαradiation ( intensity ratioλ2 / λ1=0.50) , is employed.
[0075] In certain embodiments, Form C of BUDC, having an X-ray powder diffraction (XRPD) pattern comprising one or more peaks at 2θvalues selected from the group consisting of: 7.23, 10.42, 12.10, 13.37, 14.24, 14.48, 15.28, 15.95, 17.00, 18.17, 20.12, 21.77 and 25.47° (±0.2°) obtained using Cu Kαradiation ( intensity ratioλ2 / λ1=0.50) , is employed.
[0076] In certain embodiments, Form D of BUDC, having an X-ray powder diffraction (XRPD) pattern comprising one or more peaks at 2θvalues selected from the group consisting of: 4.24, 6.79, 8.50, 10.25, 11.50, 13.62, 14.74, 15.20, 17.92, 18.39, 22.91 and 25.73° (±0.2°) obtained using Cu Kαradiation ( intensity ratioλ2 / λ1=0.50) , is employed.
[0077] In certain embodiments, Form E of BUDC, having an X-ray powder diffraction (XRPD) pattern comprising one or more peaks at 2θvalues selected from the group consisting of: 8.59, 10.55, 11.36, 11.86, 12.46, 13.08, 13.38, 14.34, 15.57, 17.24, 17.72, 18.43, 19.66, 19.84, 20.35, 20.91, 21.36, 21.95, 23.21, 24.67, 25.04, 25.82, 26.12, 27.01, 27.84, 28.97, 30.35, 33.33, 34.54 and 36.06° (±0.2°) obtained using Cu Kαradiation ( intensity ratioλ2 / λ1=0.50) , is employed.
[0078] In certain embodiments, Form H of BUDC, having an X-ray powder diffraction (XRPD) pattern comprising one or more peaks at 2θvalues selected from the group consisting of: 13.05, 14.63 and 25.46° (±0.2°) obtained using Cu Kαradiation ( intensity ratioλ2 / λ1=0.50) , is employed.
[0079] In certain embodiments, Form I of BUDC, having an X-ray powder diffraction (XRPD) pattern comprising one or more peaks at 2θvalues selected from the group consisting of: 4.19, 7.64, 10.03, 13.32, 13.84, 14.83, 16.73, 22.73, 25.61 and 28.57° (±0.2°) obtained using Cu Kαradiation ( intensity ratioλ2 / λ1=0.50) , is employed.
[0080] In certain embodiments, Form J of BUDC, having an X-ray powder diffraction (XRPD) pattern comprising one or more peaks at 2θvalues selected from the group consisting of: 4.61, 6.32, 7.38, 8.22, 9.21, 10.57, 11.73, 12.13, 12.62, 12.96, 13.87, 14.55, 14.78, 15.81, 16.48, 17.69, 18.39, 19.01, 20.06, 21.25, 22.13, 23.20, 24.47, 24.89, 26.31, 27.98, 30.25 and 33.35° (±0.2°) obtained using Cu Kαradiation ( intensity ratioλ2 / λ1=0.50) , is employed.
[0081] In certain embodiments, Form P of BUDC, having an X-ray powder diffraction (XRPD) pattern comprising one or more peaks at 2θvalues selected from the group consisting of: 3.11, 5.01, 5.78, 7.26, 9.20, 10.10, 10.79, 11.65, 13.70, 14.59, 15.22, 16.19, 16.54, 17.05, 18.06, 18.68, 20.52, 21.09, 21.73, 22.49, 24.73, 25.42, 25.94 and 30.11° (±0.2°) obtained using Cu Kαradiation ( intensity ratioλ2 / λ1=0.50) , is employed.
[0082] In certain embodiments, Form W of BUDC, having an X-ray powder diffraction (XRPD) pattern comprising one or more peaks at 2θvalues selected from the group consisting of: 6.49, 7.16, 8.51, 10.21, 12.01, 13.13, 13.90, 14.42, 15.18, 15.57, 16.03, 16.45, 16.74, 17.08, 17.85, 18.39, 19.61, 20.43, 21.39, 21.70, 23.51 and 25.21° (±0.2°) obtained using Cu Kαradiation ( intensity ratioλ2 / λ1=0.50) , is employed.
[0083] In certain embodiments, Form X of BUDC, having an X-ray powder diffraction (XRPD) pattern comprising one or more peaks at 2θvalues selected from the group consisting of: 3.63, 6.61, 7.24, 10.49, 11.95, 13.51, 14.26, 14.54, 15.14, 16.01, 16.82, 18.28, 20.26, 21.08, 21.49, 21.90, 25.60, 26.40, 27.31, 29.34, 30.59, 31.01, 34.04, 34.68 and 36.91° (±0.2°) obtained using Cu Kαradiation ( intensity ratioλ2 / λ1=0.50) , is employed.
[0084] In certain embodiments, the solid or crystalline form (e.g., Form A of BUDC) is a hydrate of BUDC. In certain embodiments, the solid or crystalline form (e.g., Form A of BUDC) is a hemi-nonahydrate of BUDC.
[0085] In certain embodiments, the solid or crystalline form (e.g., Form A of BUDC) is crystalline.
[0086] In certain embodiments, the solid or crystalline form is Form A of BUDC.
[0087] In certain embodiments, the crystalline form is characterized in a monoclinic crystal system and P21 space group. In certain embodiments of the crystalline form, each unit cell contains two asymmetric units and there are two BBR cations, two UDCA anions and nine H2O molecules per asymmetric unit, and four BBR cations, four UDCA anions and eighteen H2O molecules per unit cell.
[0088] In certain embodiments, the solid or crystalline form is Form D of BUDC.
[0089] Possible formulations include those suitable for oral, sublingual, buccal, parenteral (for example subcutaneous, intramuscular, or intravenous) , rectal, topical including transdermal, intranasal and inhalation administration. Most suitable means of administration for a particular patient will depend on the nature and severity of the disease or condition being treated or the nature of the therapy being used and on the nature of the active compound.
[0090] Compounds of the present invention are, subsequent to their preparation, preferably isolated and purified to obtain a composition containing an amount by weight equal to or greater than 95% ( “substantially pure” ) , which is then used or formulated as described herein. In certain embodiments, the compounds of the present invention are more than 99%pure.
[0091] The following examples are meant to be illustrative of the practice of the invention and not limiting in any way. Examples Example 1. Efficacy of HTD1801 on Dihydrotestosterone (DHT) -induced PCOS in RatsMethods
[0092] Postnatal 14 days female SD rats were purchased and housed under controlled lighting (12 h light, 12 h darkness, lights were turned on at 08: 00 and turned off at 20: 00) and temperature (24 ℃) with free access to food and water for a week of acclimatization.
[0093] A total of24 Postnatal 21 days rats were continuously exposed to dihydrotestosterone (DHT) from puberty to adult age to develop PCOS characteristics as previously described (Louise, et al. 2007 Endocrinology, Volume 148, Issue 8) , and blank implants were implanted into 8 postnatal 21 days rats as the control group. After 28 days of DHT exposure, 24 rats were randomized into three groups (n=8 / group) : PCOS group (0.5%CMC-Na) , positive group (300 mg / kg metformin) , and HTD1801 group (200 mg / kg HTD1801) . The first administration day was defined as Day 1, each group was administered with the corresponding test article while the control group and PCOS group received 0.5%CMC-Na, once daily by intragastric gavage for 56 days.
[0094] Body weight was recorded once a week during the treatment period.
[0095] Vaginal smears were carried out on all the rats at 9: 00 am daily using cotton bud immersed in 0.9%saline. A cotton bud was then rolled to the glass slide to collect the vaginal secretion. Estrous cycles were tracked from Day 28 to Day 35.
[0096] On Day 50, all rats fasted for 12 h and the serum was collected to measure glucose and insulin levels using ACCU-CHEK blood glucose meter and ELISA kit. Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) was calculated as follows: HOMA-IR= (fasting glucose [mg / dL] *fasting insulin [mU / L] ) / 405
[0097] At the end of the study (Day 56) , serum was collected for biochemical assays, including cholesterol, triglycerides and Low-Density Lipoprotein Cholesterol (LDL-c) . Ovarian weight and uterine weight were recorded and was used to calculate the ovarian index and uterine index. Ovarian were collected for histopathological observation of hematoxylin and eosin (H&E) staining. The number of cysts and corpus luteum were counted throughout each ovary serial segment.
[0098] The data was presented as a mean±SEM. T-test, one-way ANOVA, or Tukey’s multiple comparison tests were used to determine the differences between the groups using GraphPad Software. Statistical significance was defined as p<0.05. ResultsBody weight
[0099] The results of body weight are shown in FIG. 1. One week after DHT implantation, the body weights of the rats in the PCOS group surpassed those of the rats in the control group, while the gap between the control and PCOS group gradually increased over time. Compared with PCOS group, rats in the HTD1801 group exhibited significantly reduced body weight, while the metformin group demonstrated a more moderate decline, indicating that HTD1801 had a weight loss effect in the PCOS rats.Estrous cycles
[0100] The results of the percentage of diestrus days are shown in FIG. 2. Rats in the control group showed a regular estrus cyclicity, while rats in the PCOS group exhibited a significantly higher percentage of diestrus days than control rats. Treatment of the PCOS group with 300 mg / kg metformin or 200 mg / kg HTD1801 significantly lowered the percentage of the diestrus day compared with the PCOS group.Fasting glucose, fasting insulin andHOMA-IR
[0101] The results of the levels of fasting glucose, fasting insulin and HOMA-IR are shown in FIG. 3. Compared with the control group, fasting blood glucose in the PCOS rats showed no significant change, whereas fasting insulin level and HOMA-IR were markedly elevated, indicating that PCOS rats developed hyperinsulinemia and severe insulin resistance. Compared with PCOS group, treatment of PCOS rats with 300 mg / kg metformin or 200 mg / kg HTD1801 significantly decreased insulin levels and HOMA-IR.Serum lipid profiles
[0102] The results of the serum levels of cholesterol, triglycerides and LDL-c are shown in FIG. 4. Compared with the control group, there was no significant change in cholesterol level in the PCOS rats. The triglyceride level was markedly increased. The LDL‐c level showed an upward trend without statistical difference. Compared with the PCOS group, the positive group exhibited decreasing trends in triglyceride and LDL‐c levels, yet neither reached statistical significance. In the HTD1801 group, triglyceride level was significantly reduced, and LDL‐c level presented a downward trend. Moreover, the LDL‐c level in the HTD1801 group was comparable to that in the control group.Ovarian weight and uterine weight
[0103] The results of the ovarian weight and uterine weight are shown in FIG. 5. The total ovary weight and relative ovary weight of the DHT-treated group were significantly lower than those of the control.
[0104] Compared with the control group, the ovarian and uterine weights ofrats were significantly decreased after DHT exposure in the PCOS group. Administration of the positive drug metformin and test article HTD1801 both alleviated the reduction in ovarian and uterine weights. Notably, compared with the PCOS group, the ovarian and uterine weights in the HTD1801 group were significantly increased.H&E staining of ovaries
[0105] Ovaries in the control group displayed heterogeneous follicle populations uniformly distributed throughout the cortex, with no apparent cystic enlargement. Large, eosinophilic (pink-stained) corpora lutea were present in several sections. Ovaries in the PCOS group showed abundant cystic follicles with significantly dilated antral cavities, and corpora lutea were almost absent. Following HTD1801 treatment, cystic follicle counts and cross-sectional areas were markedly decreased, with eosinophilic corpora lutea reappearing in some sections. The results of the cysts follicle count and corpus luteum count from H&E staining of ovaries are shown in FIG. 6. Compared with the control group, the number of cysts follicle count were significantly increased, while corpus luteum count were significantly decreased after DHT exposure in the PCOS group. Administration of the positive drug metformin and test article HTD1801 both decreased the count of cysts follicle and increased the reduction in corpus luteum count. Notably, compared with the PCOS group, the number of cysts follicle count was significantly decreased and the number of corpus luteum count was significantly increased. Incorporation by Reference
[0106] References and citations to other documents, such as patents, patent applications, patent publications, journals, books, papers, web contents, have been made in this disclosure. All such documents are hereby incorporated herein by reference in their entirety for all purposes. Any material, or portion thereof, that is said to be incorporated by reference herein, but which conflicts with existing definitions, statements, or other disclosure material explicitly set forth herein is only incorporated to the extent that no conflict arises between that incorporated material and the present disclosure material. In the event of a conflict, the conflict is to be resolved in favor of the present disclosure as the preferred disclosure. Equivalents
[0107] The representative examples disclosed herein are intended to help illustrate the invention, and are not intended to, nor should they be construed to, limit the scope of the invention. Indeed, various modifications of the invention and many further embodiments thereof, in addition to those shown and described herein, will become apparent to those skilled in the art from the full contents of this document, including the examples which follow and the references to the scientific and patent literature cited herein. The above examples contain important additional information, exemplification and guidance that can be adapted to the practice of this invention in its various embodiments and equivalents thereof.
Claims
1.A method for treating polycystic ovary syndrome (PCOS) , or a related disease or condition, comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising berberine ursodeoxycholate (BUDC) .2.The method of claim 1, wherein the subject suffers from one or more symptoms associated with PCOS selected from polycystic ovaries, infertility, hyperandrogenism and irregular menstrual cycles.3.The method of claim 2, for treating polycystic ovaries.4.The method of claim 2, for treating infertility associated with PCOS.5.The method of claim 2, for treating hyperandrogenism associated with PCOS.6.The method of claim 2, for treating irregular menstrual cycles associated with PCOS.7.The method of any one of claims 1-6, wherein the subject is administered from about 500 mg / day to about 2, 500 mg / day of BUDC.8.The method of any one of claims 1-6, wherein the subject is treated for a period of about 2 weeks to about 12 months.9.The method of claim 8, wherein the subject is treated for a period of about 1 month to about 6 months.10.The method of any one of claims 1-9, wherein BUDC is in the form of Form A.11.The method of any one of claims 1-10, wherein BUDC is a hydrate.12.The method of claim 11, wherein BUDC is a hemi-nonahydrate.13.The method of any of claims 1-12, wherein BUDC is administered as a monotherapy.14.The method of any of claims 1-12, wherein BUDC is administered one or more other therapy / therapies in addition to BUDC.15.The method of any of claims 1-12, wherein BUDC is administered as an adjuvant.16.A unit dosage form for treating polycystic ovary syndrome (PCOS) , or a related disease or condition, comprising from about 250 mg to about 2,500 mg of BUDC and a pharmaceutically acceptable excipient, carrier, or diluent.17.The unit dosage form of claim 16, wherein for treating one or more symptoms associated with PCOS selected from polycystic ovaries, infertility, hyperandrogenism and irregular menstrual cycles.18.A method for treating polycystic ovary syndrome (PCOS) , or a related disease or condition, comprising administering to a subject in need thereof (i) a therapeutically effective amount of berberine (BBR) , or a pharmaceutically acceptable form thereof, and (ii) a therapeutically effective amount of ursodeoxycholic acid (UDCA) , or a pharmaceutically acceptable form thereof.19.The method of claim 18, wherein the subject suffers from one or more symptoms associated with PCOS selected from polycystic ovaries, infertility, hyperandrogenism and irregular menstrual cycles.20.The method of claim 19, for treating polycystic ovaries.21.The method of claim 19, for treating infertility associated with PCOS.22.The method of claim 19, for treating hyperandrogenism associated with PCOS.23.The method of claim 19, for treating irregular menstrual cycles associated with PCOS.24.A kit comprising (i) a unit dosage form of BBR, (ii) a unit dosage form of UDCA, and (iii) instructions for administration thereof for treating polycystic ovary syndrome (PCOS) or a related disease or condition.25.The kit of claim 24, for treating one or more symptoms associated with PCOS selected from polycystic ovaries, infertility, hyperandrogenism and irregular menstrual cycles.26.Use of (a) a therapeutically effective amount of berberine ursodeoxycholate (BUDC) , or a pharmaceutically acceptable form thereof, for treating polycystic ovary syndrome (PCOS) , or a related disease or condition.27.The use of claim 26, for treating one or more symptoms associated with PCOS selected from polycystic ovaries, infertility, hyperandrogenism and irregular menstrual cycles.28.Use of (i) a therapeutically effective amount of berberine (BBR) , or a pharmaceutically acceptable form thereof, and (ii) a therapeutically effective amount of ursodeoxycholic acid (UDCA) , or a pharmaceutically acceptable form thereof, for treating polycystic ovary syndrome (PCOS) , or a related disease or condition.29.The use of claim 28, for treating one or more symptoms associated with PCOS selected from polycystic ovaries,infertility,hyperandrogenism and irregular menstrual cycles.
